Valuation: Atossa Genetics Inc

Market Cap 2.18Cr 1.91Cr 1.79Cr 1.64Cr 3.07Cr 208.39Cr 3.09Cr 22Cr 8.36Cr 106.25Cr 8.17Cr 7.99Cr 344.48Cr P/E 2026 *
-0.57x
P/E 2027 * -0.69x
Enterprise Value 2.18Cr 1.91Cr 1.79Cr 1.64Cr 3.07Cr 208.39Cr 3.09Cr 22Cr 8.36Cr 106.25Cr 8.17Cr 7.99Cr 344.48Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Genetics Inc

Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
+27.09%-30.98% - - 2.18Cr
+1.00%+3.67%+7.70%+30.76% 4.76TCr
-0.83%-0.36%+43.66%+34.77% 4.41TCr
-0.84%+4.86%+10.92%+91.52% 4.15TCr
-1.10%-2.64%+331.49%+535.80% 4.09TCr
-0.62%+0.11%+1.12%+46.02% 2.97TCr
-2.07%+0.12%+24.39%+154.30% 1.72TCr
+1.22%+0.27%+24.54%+40.83% 1.51TCr
-6.08%-9.92% - - 1.47TCr
-0.78%+9.46%-8.96% - 1.38TCr
Average +1.61%+0.69%+54.36%+133.43% 2.94TCr
Weighted average by Cap. -0.82%+0.96%+68.03%+141.26%

Financials

2026 *2027 *
Net sales - -
Net income -3.49Cr -3.06Cr -2.88Cr -2.63Cr -4.92Cr -334.25Cr -4.95Cr -35Cr -13Cr -170.41Cr -13Cr -13Cr -552.51Cr -3.8Cr -3.34Cr -3.14Cr -2.87Cr -5.36Cr -364.25Cr -5.4Cr -38Cr -15Cr -185.71Cr -14Cr -14Cr -602.11Cr
Net Debt - -
Logo Atossa Genetics Inc
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-